WTX 225
Alternative Names: WTX-225Latest Information Update: 07 Aug 2022
At a glance
- Originator Westlake Therapeutics
- Class Anti-infectives; Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Sepsis
Most Recent Events
- 07 Aug 2022 Westlake Therapeutics has patent protection for Modified red blood cells and uses thereof for delivering agents
- 25 Jul 2022 Westlake Therapeutics has patent protection for the development of red blood cell therapy technology (Westlake Therapeutics website; July 2022)
- 20 Jul 2022 Early research in Inflammation in China (Parenteral) (Westlake Therapeutics pipeline; July 2022)